Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/50

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/076841METHODS FOR ULTRASENSITIVE DETECTION OF PROTEIN AND CELLULAR BIOMARKERS
WO 22.04.2021
Int.Class C12Q 1/6825
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
6816characterised by the detection means
6825Nucleic acid detection involving sensors
Appl.No PCT/US2020/055904 Applicant GEORGIA TECH RESEARCH CORPORATION Inventor KWONG, Gabriel, A.
CRISPR-based diagnostic methods and compositions are provided. One embodiment provides the use of DNA-barcoded antibodies or peptide-MHC (pMHC) tetramers (e.g., Kb-OVA257-264, Db-GP10025-33, Db-GP33-41) and CRISPR-Cas protein, and a guided DNA endonuclease, to achieve ultrasensitive detection of soluble and cell surface proteins. The disclosed embodiments can use type V: Cas12a; type VI: Cas13a, or Cas13b. Combining DNA encoding with CRISPR-Cas protein recognition is a sensitive system because barcodes can be isothermally amplified and Cas, for example Cas12a, enzymatically cleaves DNA reporters upon barcode detection, providing two rounds of amplification and enabling measurement of protein concentration by sample fluorescence or using by paper-based assays. This platform enables monitoring of protein and cellular biomarkers and further expands the toolbox of CRISPR/Cas-based technologies
2.112641938一种DNA重组干细胞载体新冠疫苗
CN 13.04.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202011375242.0 Applicant 翁炳焕 Inventor 翁炳焕
一种DNA重组干细胞载体新冠疫苗,其特征在于,从干细胞样本库或日常实验后剩余的样本中获得间充质干细胞或羊水成纤维细胞,筛选、诱导成肺干细胞,然后将新冠病毒的易感基因ACE2插入已被永生化基因SV40LT和/或hTERT转染的干细胞DNA中,制备易被新冠病毒感染的易感干细胞;进而将新冠病毒M、N、E和/或S基因的RNA干扰序列shRNA插入所述易感干细胞DNA中,制备能通过ACE2将新冠病毒吸入干细胞内并能通过shRNA靶向干扰新冠病毒在干细胞内复制的DNA重组干细胞;最后将新冠病毒抗体产生基因S1‑RBD插入所述重组干细胞DNA中,制备易将新冠病毒竞争吸入干细胞内进行RNA干扰、能在体外产业化扩增并能产生新冠病毒中和抗体的DNA重组干细胞载体新冠疫苗。
3.112646823一种基因编辑新冠疫苗载体的制备方法
CN 13.04.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 202011375481.6 Applicant 翁炳焕 Inventor 翁炳焕
一种基因编辑新冠疫苗载体的制备方法,其特征在于,以新冠病毒易感受体ACE2基因编辑、SV40LT和/或hTERT基因转染的方法将原本弃用的产前诊断后剩余羊水细胞、新生儿脐血、脐带、胎盘等组织细胞改造为兼具干细胞天然治疗功能、无限传代的永生化功能、新冠病毒ACE2受体缺失特性的可再生利用的新冠疫苗载体,专用于制备个体化治疗COVID‑19的疫苗,可按姓名、ABO血型或HLA分型长期预存于‑196℃干细胞库,当新冠病毒传染病流行或某个体需要使用时,可选择自身或同型的基因编辑永生干细胞系传代扩增后进行干细胞治疗或疫苗制备,以消除、减少传统干细胞治疗和疫苗使用中的免疫排斥反应。
4.112625096一种禽传染性支气管炎病毒样颗粒及其制备方法与应用
CN 09.04.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202110049762.0 Applicant 广西大学 Inventor 磨美兰
本发明公开了一种禽传染性支气管炎病毒样颗粒,所述病毒样颗粒由IBV‑S、IBV‑M、IBV‑E基因分别转入到杆状病毒表达系统中,获得3种重组杆粒,再分别将3种重组杆粒转染到昆虫细胞中,获得重组杆状病毒rHBM‑S、rHBM‑M和rHBM‑E,然后通过共感染的形式,初步构建得到,该病毒样颗粒应用于制备疫苗中,具有巨大的开发潜力。
5.112626089一种SARS-CoV-2病毒S蛋白受体结合区域编码基因、抗体及应用
CN 09.04.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 202011445642.4 Applicant 杭州百凌生物科技有限公司 Inventor 潘丽
本发明公开了一种SARS‑CoV‑2病毒S蛋白受体结合区域编码基因表达的重组蛋白、其产生的抗体及应用,属于生物医学领域及免疫学检测领域。所述编码基因具有SEQ ID NO:2所示的核苷酸序列。所述编码基因或抗体可应用于制备检测抗SARS‑CoV‑2病毒S蛋白受体结合区域抗体。本发明公开了利用所述编码基因表达的重组蛋白制备的抗体及其应用。本发明的编码基因保证了蛋白表达的唯一性,减少了蛋白后续纯化的难度。制备的抗体检测抗原的灵敏度高、特异性强。
6.112618707一种SARS-CoV-2冠状病毒疫苗及其制备方法
CN 09.04.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202011103983.3 Applicant 广州达博生物制品有限公司 Inventor 黄文林
本发明公开了一种SARS‑CoV‑2冠状病毒的疫苗及其制备方法,通过对SARS‑CoV‑2冠状病毒的S基因进行密码子优化,并将S基因的截短体及突变体序列导入分泌型缺陷型腺病毒载体,包装得到相应重组腺病毒。该重组腺病毒能够在体内表达SARS‑CoV‑2病毒相关蛋白,并完成加工、折叠、糖基化等修饰,基本上保持S蛋白的天然构象,具有生物活性高、半衰期长、免疫原性持久等特点。本品采用的携带分泌肽的缺陷型腺病毒载体使重组腺病毒疫苗在体内表达后,能被分泌至细胞外,从而激活体液免疫。
7.112618708一种hACE2敲除的RNA干扰干细胞载体新冠疫苗
CN 09.04.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202011375244.X Applicant 翁炳焕 Inventor 翁炳焕
一种hACE2敲除的RNA干扰干细胞载体新冠疫苗,其特征在于,以hACE2基因敲除的RNA干扰干细胞取代传统新型冠状病毒疫苗的腺病毒载体。所述RNA干扰干细胞,为一种在敲除新冠病毒易感基因ACE2、转染永生化基因SV40LT和/或hTERT的基础上重组新冠病毒M、N、E和/或S基因的靶向干扰基因shRNA的干细胞。这种RNA干扰干细胞具有抵抗新冠病毒感染、无限传代、抑制新冠病毒在干细胞内复制的功能,可按姓名、ABO血型或HLA分型长期预存于‑196℃干细胞库备用,不但可取同型干细胞个体化治疗COVID‑19,还可取代具有免疫源性的腺病毒载体,将新冠病毒抗体产生基因S1‑RBD插入RNA干扰干细胞DNA中,制备能产生新冠病毒中和抗体的RNA干扰干细胞载体疫苗。
8.112630427一种基于S1蛋白的检测流行QX型鸡传染性支气管病毒抗体的间接免疫荧光试剂盒
CN 09.04.2021
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No 202011371468.3 Applicant 扬州大学 Inventor 叶建强
本发明公开了一种基于S1蛋白的检测流行QX型鸡传染性支气管病毒抗体的间接免疫荧光试剂盒,该试剂盒包括表达S1蛋白的LMH细胞,FITC标记的羊抗鸡抗体,样品稀释液,洗涤液。本发明试剂盒具有良好的特异性;该试剂盒不仅能用于QX型鸡传染性支气管病毒感染状况流行病学调查,而且能有效用于监测免疫鸡群QX型鸡传染性支气管病毒抗体水平,用于评价免疫保护性抗体水平等。
9.112626123重组质粒、重组基因VII型新城疫病毒及其培养方法
CN 09.04.2021
Int.Class C12N 15/85
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
Appl.No 202011642554.3 Applicant 华农(肇庆)生物产业技术研究院有限公司 Inventor 叶俊贤
本发明属于生物领域,公开了一种重组质粒pBR322‑FDHN3‑S1,其序列如序列表SEQ ID NO:1所示。该重组质粒采用强毒性的VII亚型NDV毒株DHN3株为基础,用Lasota弱毒株的F基因替换了DHN3株的F基因,插入S1基因,针对II型、VII型新城疫和IBV具有免疫源性。同时,本发明还公开了一种重组病毒以及针对该病毒的高滴度培养方法。
10.112626090一种编码新型冠状病毒抗原的核苷酸序列及其应用
CN 09.04.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 202011597679.9 Applicant 艾棣维欣(苏州)生物制药有限公司 Inventor 俞庆龄
本发明提供了一种编码新型冠状病毒抗原的核苷酸序列及其应用。本发明将编码SARS‑CoV‑2病毒表面蛋白Spike的野生型DNA序列进行优化,并将其野生型基因信号肽优化后插入真核表达载体,将其导入宿主细胞,使其在宿主细胞内高效表达病毒Spike抗原,经过抗原提呈后系统地激活抗病毒体液免疫应答及细胞免疫应答。激活的体液免疫应答所产生的抗体可以预防SARS‑CoV‑2病毒的侵入,激活的细胞免疫应答可进一步清除受病毒感染的细胞,并调节由于ADE的潜在副作用而引发的不良反应。